WO2000037094A2 - Applications therapeutiques de polypeptides flint - Google Patents

Applications therapeutiques de polypeptides flint Download PDF

Info

Publication number
WO2000037094A2
WO2000037094A2 PCT/US1999/030734 US9930734W WO0037094A2 WO 2000037094 A2 WO2000037094 A2 WO 2000037094A2 US 9930734 W US9930734 W US 9930734W WO 0037094 A2 WO0037094 A2 WO 0037094A2
Authority
WO
WIPO (PCT)
Prior art keywords
mflint
cells
fasl
flint
fas
Prior art date
Application number
PCT/US1999/030734
Other languages
English (en)
Other versions
WO2000037094A3 (fr
Inventor
Fredric Jay Cohen
James Arthur Posada
Daniel Wierda
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/006797 external-priority patent/WO1999050413A2/fr
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Priority to JP2000589204A priority Critical patent/JP2003520761A/ja
Priority to AU22111/00A priority patent/AU2211100A/en
Priority to EP99966602A priority patent/EP1140138A2/fr
Priority to CA002358508A priority patent/CA2358508A1/fr
Publication of WO2000037094A2 publication Critical patent/WO2000037094A2/fr
Publication of WO2000037094A3 publication Critical patent/WO2000037094A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

la protéine FLINT mature (mFLINT) se lie avec FasL et LIGHT, et empêche une interaction FasL-Fas. La protéine mature mFLINT inhibe l'activité apoptotique et pro-inflammatoire à médiation FasL-Fas, et convient pour le traitement de troubles associés à une apoptose et à une inflammation anormales. L'invention concerne des séquences d'amino-acides et de nucléotides de FLINT et de FLINT mature. Elle porte également sur des compositions thérapeutiques et sur des méthodes de traitement faisant intervenir mFLINT.
PCT/US1999/030734 1998-12-22 1999-12-21 Applications therapeutiques de polypeptides flint WO2000037094A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000589204A JP2003520761A (ja) 1998-12-22 1999-12-21 Ｆｌｉｎｔポリペプチドの治療用への適用
AU22111/00A AU2211100A (en) 1998-12-22 1999-12-21 Therapeutic applications of flint polypeptides
EP99966602A EP1140138A2 (fr) 1998-12-22 1999-12-21 Applications therapeutiques de polypeptides flint
CA002358508A CA2358508A1 (fr) 1998-12-22 1999-12-21 Applications therapeutiques de polypeptides flint

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11340798P 1998-12-22 1998-12-22
US60/113,407 1998-12-22
USPCT/US99/06797 1999-03-30
PCT/US1999/006797 WO1999050413A2 (fr) 1998-03-30 1999-03-30 APPLICATIONS THERAPEUTIQUES DE POLYPEPTIDES mFLINT MURS, OU DE OPG3 EN TANT QUE MEMBRE DE LA SUPERFAMILLE DU RECEPTEUR DU TNF
US17223999P 1999-10-20 1999-10-20
US60/172,239 1999-10-20

Publications (2)

Publication Number Publication Date
WO2000037094A2 true WO2000037094A2 (fr) 2000-06-29
WO2000037094A3 WO2000037094A3 (fr) 2000-11-09

Family

ID=27378725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/030734 WO2000037094A2 (fr) 1998-12-22 1999-12-21 Applications therapeutiques de polypeptides flint

Country Status (5)

Country Link
EP (1) EP1140138A2 (fr)
JP (1) JP2003520761A (fr)
AU (1) AU2211100A (fr)
CA (1) CA2358508A1 (fr)
WO (1) WO2000037094A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002009668A2 (fr) * 2000-08-02 2002-02-07 Eli Lilly And Company Administration de flint (proteine inhibitrice du ligand fas) par voie pulmonaire
US7186800B1 (en) 1997-01-14 2007-03-06 Human Genome Sciences, Inc. Tumor necrosis factor 6α and 6β
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
WO2022074236A3 (fr) * 2020-10-09 2022-07-07 Ucl Business Ltd Traitement thérapeutique

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030694A2 (fr) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. RECEPTEURS 6α ET 6β DU FACTEUR DE NECROSE TUMORALE
EP0861850A1 (fr) * 1997-02-04 1998-09-02 Smithkline Beecham Corporation Récepteurs TR4, liés à la nécrose tumorale
WO1999004001A1 (fr) * 1997-07-21 1999-01-28 Zymogenetics, Inc. Recepteur ztnfr-5 du facteur de necrose tumorale
WO1999007738A2 (fr) * 1997-08-06 1999-02-18 Regeneron Pharmaceuticals, Inc. Nouveau recepteur orphelin
WO1999014330A1 (fr) * 1997-09-18 1999-03-25 Genentech, Inc. HOMOLOGUE DU TNFR APPELE POLYPEPTIDE DcR3
WO1999026977A1 (fr) * 1997-11-24 1999-06-03 Biogen, Inc. Recepteurs 'opg-2'
WO1999050413A2 (fr) * 1998-03-30 1999-10-07 Eli Lilly And Company APPLICATIONS THERAPEUTIQUES DE POLYPEPTIDES mFLINT MURS, OU DE OPG3 EN TANT QUE MEMBRE DE LA SUPERFAMILLE DU RECEPTEUR DU TNF

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030694A2 (fr) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. RECEPTEURS 6α ET 6β DU FACTEUR DE NECROSE TUMORALE
EP0861850A1 (fr) * 1997-02-04 1998-09-02 Smithkline Beecham Corporation Récepteurs TR4, liés à la nécrose tumorale
WO1999004001A1 (fr) * 1997-07-21 1999-01-28 Zymogenetics, Inc. Recepteur ztnfr-5 du facteur de necrose tumorale
WO1999007738A2 (fr) * 1997-08-06 1999-02-18 Regeneron Pharmaceuticals, Inc. Nouveau recepteur orphelin
WO1999014330A1 (fr) * 1997-09-18 1999-03-25 Genentech, Inc. HOMOLOGUE DU TNFR APPELE POLYPEPTIDE DcR3
WO1999026977A1 (fr) * 1997-11-24 1999-06-03 Biogen, Inc. Recepteurs 'opg-2'
WO1999050413A2 (fr) * 1998-03-30 1999-10-07 Eli Lilly And Company APPLICATIONS THERAPEUTIQUES DE POLYPEPTIDES mFLINT MURS, OU DE OPG3 EN TANT QUE MEMBRE DE LA SUPERFAMILLE DU RECEPTEUR DU TNF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
G. MATUTE-BELLO ET AL: "Soluble Fas Ligand induces epithelial cell apoptosis in humans with acute lung injury (ARDS)" JOURNAL OF IMMUNOLOGY., vol. 163, no. 4, 15 August 1999 (1999-08-15), pages 2217-2225, XP002137439 BALTIMORE US *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186800B1 (en) 1997-01-14 2007-03-06 Human Genome Sciences, Inc. Tumor necrosis factor 6α and 6β
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
US7534428B2 (en) 1997-01-14 2009-05-19 Human Genome Sciences, Inc. Antibodies to tumor necrosis factor receptors 6α and 6β
US7709218B2 (en) 1997-01-14 2010-05-04 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α and 6β
WO2002009668A2 (fr) * 2000-08-02 2002-02-07 Eli Lilly And Company Administration de flint (proteine inhibitrice du ligand fas) par voie pulmonaire
WO2002009668A3 (fr) * 2000-08-02 2002-05-10 Lilly Co Eli Administration de flint (proteine inhibitrice du ligand fas) par voie pulmonaire
WO2022074236A3 (fr) * 2020-10-09 2022-07-07 Ucl Business Ltd Traitement thérapeutique

Also Published As

Publication number Publication date
AU2211100A (en) 2000-07-12
WO2000037094A3 (fr) 2000-11-09
CA2358508A1 (fr) 2000-06-29
EP1140138A2 (fr) 2001-10-10
JP2003520761A (ja) 2003-07-08

Similar Documents

Publication Publication Date Title
US20040167074A1 (en) Therapeutic applications of mFLINT polypeptides
JP4411330B2 (ja) 腫瘍壊死因子関連リガンド
US6207802B1 (en) Stem cell factor and compositions
US7067477B2 (en) Canine erythropoietin gene and recombinant protein
US6248319B1 (en) Method for increasing hematopoietic progenitor cells by stem cell factor polypeptides
EP1326974B1 (fr) Procedes relatifs a l'utilisation de polypeptide lie a l'interleukine 17 (il-17) humaine pour le traitement de maladies-
WO1997047321A1 (fr) Utilisation de proteines chimeres regulatrices du complement du virus vaccinal pour inhiber ledit complement
JP3750819B2 (ja) Ｃ−ｋｉｔ受容体に対するリガンド及びその使用法
US7144731B2 (en) SCF antibody compositions and methods of using the same
JPH08501314A (ja) Ｈｇｆによる肝臓障害に対する保護
US20050054567A1 (en) Use of il-19,il-22 and il-24 to treat hematopoietic disorders
JP2005506287A5 (fr)
EP0639225B1 (fr) Nouveaux polypeptides et peptides, acides nucleiques codant pour ceux-ci, et leur emploi en therapie des tumeurs, en inflammation ou en immunologie
WO2000037094A2 (fr) Applications therapeutiques de polypeptides flint
US6207454B1 (en) Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
ZA200005157B (en) Therapeutic applications of mature flint (mFLINT) polypeptides or OPG3, a member of the TNF receptor superfamily.
US20040236088A1 (en) Novel polypeptide analogs and fusions and their methods of use
MXPA00009523A (en) THERAPEUTIC APPLICATIONS OF MATURE FLINT (mFLINT) POLYPEPTIDES OR OPG3, A MEMBER OF THE TNF RECEPTOR SUPERFAMILY
EP1225908A2 (fr) Applications therapeutiques de polypeptides de flint
US20040072745A1 (en) Therapeutic methods of use for lp229
HRP20020269A2 (en) The prv-1 gene and use thereof
WO1998055141A9 (fr) Procedes et produits pour induire l'apoptose des cellules neuroendocrines a l'aide de proteine stimulant les macrophages
AU3657599A (en) Canine erythropoietin gene and recombinant protein
WO2003065981A2 (fr) Methodes d'utilisation therapeutiques de lp229
JPH11335299A (ja) 抗癌剤または放射線療法の副作用軽減剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase in:

Ref document number: 2358508

Country of ref document: CA

Ref country code: CA

Ref document number: 2358508

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2000 589204

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999966602

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999966602

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999966602

Country of ref document: EP